MOLN Earnings Forecast
Looking ahead, MOLN remains a focal point for investors seeking growth opportunities. Analyst forecasts for project quarter revenue of and an EPS of -0.37.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted Go Up by 7.89% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in MOLN long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
1Y
3Y
5Y
Currency: USD
--
Revenue Estimate-:0
--
EPS Estimate-:0
—
Stock Price0
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Unlock the reason behind revisions!
Stock Price
Go Up
+7.89%
In Past 3 Month
No data
Earnings Surprise Analysis
Revenue
EPS
1Y
3Y
Al Analysis
Earnings Reaction
The chart below shows how MOLN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MOLN sees a -0.39% change in stock price 10 days leading up to the earnings, and a -5.29% change 10 days following the report. On the earnings day itself, the stock moves by +0.52%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in SEP/2025, the stock changed -3.62% on the day following the earnings release and then changed by 13.53% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
People Also Watch
Frequently Asked Questions
What were the key highlights of MOLN's latest earnings report for FY2025Q3?
MOLN reported its FY2025Q3 earnings on 2025-10-30, showcasing a revenue of 0.00 against an estimate of 0.00, resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.46 by 0% . The stock experienced a 6.2% price change on the earnings day and a 10.14% change over the next five days, reflecting market reactions to the results.
How did MOLN's stock price react after the FY2025Q3 earnings release?
Following MOLN's FY2025Q3 earnings announcement on 2025-10-30, the stock price moved by 6.20% on the day of the release. Over the subsequent five days, it saw a 10.14% change. Historically, MOLN's stock price tends to shift by an average of -0.39% in the 10 days leading up to earnings and -5.29% in the 10 days following, providing insight into potential market.
What are the revenue and EPS estimates for MOLN for undefined?
For , analysts estimate MOLN’s annual revenue to reach , while the EPS is projected at -0.37. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Go Up by 7.89% over the past three months, indicating analyst expectation in the company’s performance.
How does MOLN's stock price correlate with earnings forecast revisions?
The correlation between MOLN's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Go Up by 7.89% . This trend suggests that price dips could present buying opportunities for investors.
What should investors expect from MOLN's next earnings report?
Based on historical trends, MOLN's stock price typically moves by -0.39% in the 10 days before its earnings and -5.29% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.37 and revenue of .
What is the sentiment in Molecular Partners AG (MOLN) Q4 2024 Earnings Call Summary?
The earnings call reveals several challenges: revenue decline due to the end of the Novartis collaboration, cash burn, and significant risks in securing isotope supply, regulatory approvals, and clinical trials. The lack of a shareholder return plan and strategic misalignment with Novartis further weigh on sentiment. Although the cash position is stable, the reliance on external funding and competitive pressures add uncertainty. The Q&A section highlighted management's vague responses, particularly regarding clinical data timelines, adding to the negative sentiment. These factors collectively suggest a negative stock price movement in the short term.